DeNovo Sciences Appoints Dr. Yixin Wang, Former R&D Executive At Ventana And Veridex As Chief Scientific Officer

Plymouth | DeNovo Sciences, Inc. an innovator of cutting edge products of liquid biopsy, announced the appointment of Dr. Yixin Wang as Chief Scientific Officer (CSO). Dr. Wang is a veteran in molecular diagnostics where he has played significant R&D roles at large, multi-national companies including Parke-Davis/Pfizer, Veridex/Johnson & Johnson and Ventana/Roche. He will lead strategic initiatives for clinical development of DeNovo's technology in the United States and overseas. This is a great opportunity for DeNovo Sciences since Yixin brings extensive and critical expertise from his experience on development of several cancer diagnostic technologies, especially the first and only FDA approved circulating tumor cell (CTC) technology, CellSearch from Veridex.

Dr. Wang has held several R&D leadership positions prior to joining DeNovo Sciences, including Vice President, Molecular Probes at Ventana Medical Systems/Roche, a world leader of tissue-based diagnostic solutions for cancer patients; and Executive Director, R&D at Veridex, an oncology molecular and cellular diagnostic business of J&J. Yixin also has extensive experience working with pharmaceutical groups, identified molecular markers, and developed and validated companion molecular assays. Yixin earned his Ph.D. in Molecular Biology from Cornell University and his B.S. in Biochemistry from Beijing University.

"I am excited to have Dr. Wang join our DeNovo team. This marks a great validation for our technology. With Yixin's specific experience on development and commercialization of CellSearch and CTC technologies, DeNovo can now put a confident foot forward as it embarks on its own FDA trial," said Dr. Kalyan Handique, CEO, DeNovo Sciences, Inc. "During my tenure at Ventana/Roche, I collaborated with the DeNovo team on validation of its CTC technology. I strongly believe that the platform has a clear competitive advantage and a great potential to be applied in clinical diagnostics both in US and worldwide. It would enable molecular diagnostic tests on CTCs for many cancer types and pathways in order to deliver clinically relevant information to our customers. I look forward to working with the DeNovo team to take the technology to its fruition," said Dr. Wang.

###

About DeNovo Sciences, Inc.

DeNovo Sciences, Inc., a privately held Michigan based company, develops automated systems for rare CTC enrichment and single cell analysis. The JETTA 400 system performs all the required processing steps to isolate and performs downstream single cell analysis to include Immunochemistry, DNA FISH or mRNA FISH while the Vanguard analyzes the prepared slide automatically. The innovation allows the healthcare professional more time to focus on their patient's therapeutic treatment and outcome. To learn more, visit http://www.denovosciences.com/ or contact us at [email protected] or call us at 734-233-3089.

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.